Latest Breaking News On - Yoonjin cho - Page 1 : comparemela.com

REGENXBIO Announces Presentations at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2023

REGENXBIO Announces Presentations at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2023
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Israel generalUnited statesJoe hagoodRaymond wangChris brinzeyPaulo falabellaCatherine wilsonPorto alegreMichelle woodYoonjin choCaroline mulatyaPaul harmatzDivision of metabolic disordersTechnology platform licenseesTechnology platformInborn errors

REGENXBIO Announces Presentations at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2023

REGENXBIO Announces Presentations at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2023
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

Israel generalUnited statesChris brinzeyRaymond wangJoe hagoodPaulo falabellaMichelle woodYoonjin choCatherine wilsonPorto alegrePaul harmatzCaroline mulatyaDivision of metabolic disordersTechnology platformTechnology platform licenseesInborn errors

REGENXBIO Announces Presentations at the 19th Annual WORLDSymposium™ 2023

/PRNewswire/ REGENXBIO Inc. (Nasdaq: RGNX) today announced that three oral and eight poster presentations will be presented at the 19th Annual.

Nordrhein westfalenUnited statesUniversity of pennsylvaniaChristina ohnsmanRaymond wangChris brinzeyKwi hye kimKeigo takahashiYoonjin choDana cormackGary chanLuca hagenahUniversity of californiaClinical outcomes researchTechnology platformTechnology platform licensees

REGENXBIO Announces Presentations at the 18th Annual WORLDSymposium™ 2022

/PRNewswire/ Interim data from Phase I/II trials of RGX-121 for the treatment of MPS II and RGX-111 for the treatment of MPS I to be presented REGENXBIO Inc..

United statesSan diegoChristina ohnsmanRaymond wangChris brinzeyKwi hye kimLalitha belurPorto alegreRoberto giuglianiNicholas bussYoonjin choDana cormackNidal boulosCeroid lipofuscinosisUniversity of californiaPreclinical development